We are a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. We are transforming patient care by providing critical insights into what drives disease through our advanced blood and tissue tests, real-world data and AI analytics.
The business is unprofitable at the operating level (-44.53% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 32.9% YoY with margins expanding 15.5pp.
Negative free cash flow of -$233M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$1.08B
▲ +32.9% YoY
Net Income (TTM)
-$433M
▲ +4.6% YoY
Op. Margin
-41.43%
▲ +15.5pp YoY
ROIC
-23.28%
▲ +1.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$237M
▲ +15.2% YoY
Op. Cash Flow (TTM)
-$188M
▲ +23.0% YoY
Net Debt
$602M
Cash & Equiv.
$1.10B
5Y CAGR: +27.9%
Continue Research